Japan Breast Cancer Research Group
Clinical trials sponsored by Japan Breast Cancer Research Group, explained in plain language.
-
Second dose of targeted combo shows promise for tough breast cancer
Disease control CompletedThis study looked at whether giving pertuzumab again, along with trastuzumab and chemotherapy, helps people with advanced HER2-positive breast cancer live longer without their disease getting worse. About 226 adults who had already been treated with pertuzumab took part. The goal…
Phase: PHASE3 • Sponsor: Japan Breast Cancer Research Group • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New combo aims to keep cancer in check with fewer side effects
Disease control CompletedThis study tested whether a combination of eribulin, pertuzumab, and trastuzumab works as well as the standard taxane-based combo for advanced HER2-positive breast cancer, but with better quality of life. 446 women who had not received chemotherapy for advanced disease took part.…
Phase: PHASE3 • Sponsor: Japan Breast Cancer Research Group • Aim: Disease control
Last updated May 14, 2026 12:02 UTC